DERMATA THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.66 USD | +1.10% |
|
-29.62% | -60.00% |
| Mar. 21 | Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 05 | Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 14.49 | 4.95 | 2.159 | 1.607 | - | - |
| Enterprise Value (EV) 1 | 14.49 | 4.95 | 2.159 | 1.607 | 1.607 | 1.607 |
| P/E ratio | -0.72 x | -0.47 x | -0.23 x | -0.22 x | -0.79 x | -1.06 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 34.7 | 50.4 | 236 | 444.1 | - | - |
| Reference price 2 | 417.6 | 98.16 | 9.150 | 3.620 | 3.620 | 3.620 |
| Announcement Date | 3/28/22 | 2/21/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -7.857 | -9.674 | -8.042 | -13.34 | -15.73 | -16.23 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) | -7.902 | -9.611 | -7.795 | - | - | - |
| Net income 1 | -10.46 | -9.611 | -7.795 | -13.2 | -15.58 | -16.06 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -583.2 | -208.8 | -40.05 | -16.17 | -4.610 | -3.410 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 2/21/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.553 | -2.786 | -2.731 | -2.446 | -1.712 | -2.278 | -1.732 | -1.812 | -2.22 | -3.204 | -3.006 | -3.915 | -3.215 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | -2.553 | -2.786 | -2.731 | -2.425 | -1.67 | -2.24 | -1.701 | -1.719 | -2.134 | - | - | - | - |
| Net income 1 | -2.553 | -2.786 | -2.731 | -2.425 | -1.67 | -2.24 | -1.701 | -1.719 | -2.134 | -3.134 | -2.914 | -3.894 | -3.259 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -194.4 | -79.20 | -57.60 | -48.00 | -28.80 | -34.05 | -9.450 | -8.100 | -3.150 | -7.050 | -3.790 | -3.730 | -1.590 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/16/22 | 8/15/22 | 11/10/22 | 2/21/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/21/24 | 5/15/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 2/21/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.62
USD
Average target price
10
USD
Spread / Average Target
+176.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.00% | 1.61M | |
| +10.52% | 115B | |
| +12.16% | 106B | |
| -4.42% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.32% | 17.56B | |
| -40.50% | 17.32B | |
| +6.12% | 14.03B | |
| +30.92% | 12.13B |
- Stock Market
- Equities
- DRMA Stock
- Financials Dermata Therapeutics, Inc.
